Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 18.1% in February
by Amy Steele · The Cerbat GemLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the target of a large drop in short interest in February. As of February 13th, there was short interest totaling 98,894 shares, a drop of 18.1% from the January 29th total of 120,679 shares. Based on an average trading volume of 74,849 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.5% of the company’s stock are short sold. Currently, 1.5% of the company’s stock are short sold. Based on an average trading volume of 74,849 shares, the days-to-cover ratio is presently 1.3 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Get Our Latest Research Report on Lixte Biotechnology
Lixte Biotechnology Stock Down 2.7%
Lixte Biotechnology stock traded down $0.08 during midday trading on Tuesday, hitting $2.85. 35,243 shares of the stock were exchanged, compared to its average volume of 79,702. Lixte Biotechnology has a 52-week low of $0.64 and a 52-week high of $6.26. The business’s 50-day moving average price is $3.40 and its 200-day moving average price is $4.07. The stock has a market capitalization of $21.31 million, a price-to-earnings ratio of -2.42 and a beta of 0.93.
Institutional Trading of Lixte Biotechnology
A number of institutional investors and hedge funds have recently modified their holdings of LIXT. Axxcess Wealth Management LLC purchased a new position in Lixte Biotechnology in the fourth quarter worth $54,000. XTX Topco Ltd bought a new stake in shares of Lixte Biotechnology during the 4th quarter worth $57,000. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after buying an additional 42,530 shares during the last quarter. DRW Securities LLC grew its position in Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares during the period. Finally, Renaissance Technologies LLC grew its position in Lixte Biotechnology by 47.0% during the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after buying an additional 34,350 shares during the period. 5.10% of the stock is owned by hedge funds and other institutional investors.
Lixte Biotechnology Company Profile
Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.
Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.